CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M

CERO THERAPEUTICS HOLDINGS, INC.

Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.
Amendment to SPA added an additional buyer and increased initial closing by $500k; total remains $7M.
Series E preferred stock terms filed as Certificate of Designations on Oct 14, 2025.
Remaining $4.75M to be funded at additional closings under the Securities Purchase Agreement.

item 1.01item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.